The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Cancer Statistics, 2017.

Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964

Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review

Zhang, C., Yang, C., & Shi, Q. (2025) · Cancer Management and Research · doi:10.2147/cmar.s495006 · Cited by 13

Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study

Serna‐Blasco, R., Mediavilla-Medel, P., Medina, K., Sala, M. Á., Bujanda, D. A., Díaz-Serrano, A., Antoñanzas, M., Ocaña, J., Mielgo-Rubio, X., Fernández, I., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108550 · Cited by 12

Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer

Ono, A., Isaka, M., Serizawa, M., Omae, K., Kojima, H., Nakashima, K., Omori, S., Wakuda, K., Kenmotsu, H., Naito, T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.005 · Cited by 12

Radiomics for differentiating adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer beyond nodule morphology in chest CT

Selvam, M., Sadanandan, A., Chandrasekharan, A., Ramesh, S., Murali, A., & Krishnamurthi, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-83786-6 · Cited by 11

Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma

Lázaro, S., Lorz, C., Enguita, A. B., Seller‐Corona, I., Paramio, J. M., & Santos, M. (2022) · Cancers · doi:10.3390/cancers14153671 · Cited by 12

A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy

McCoach, C. E. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.009 · Cited by 11

Round Robin Evaluation of MET Protein Expression in Lung Adenocarcinomas Improves Interobserver Concordance

Boyle, T. A., Khalil, F. K., Mino-Kenudson, M. A., Sica, G., Moreira, A. L., Sholl, L. M., Knight, M. Z., Zhang, L., Saller, J. J., Varella‐Garcia, M., et al. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000810 · Cited by 11

Molecular Diagnostics in Non-Small Cell Lung Carcinoma

Sholl, L. M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399564 · Cited by 11

Malignant transformation of human bronchial epithelial cells induced by benzo [a] pyrene suggests a negative feedback of TP53 to PPP1R13L via binding a possible enhancer element

Zhang, G., Yu, T., Zhang, Q., Zhang, H., Xiao, M., Cui, S., Zhao, Y., & Lu, X. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109683 · Cited by 11

Molecular characterization of MET fusions from a large real‐world Chinese population: A multicenter study

Xia, H., Zhang, J., Chen, T., Wang, M., Chen, D., Si, T., & Liu, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.6047 · Cited by 10

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non–Small-cell Lung Cancer in Asia

Loong, H. H.-F., Raymond, V. M., Shiotsu, Y., Chua, D. T. T., Teo, P. M. L., Yung, T., Skrzypczak, S. M., Lanman, R. B., & Mok, T. S. K. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.022 · Cited by 10

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)

Hayashi, H., Yonesaka, K., Nakamura, A., Fujimoto, D., Azuma, K., Sakata, S., TACHIHARA, M. Y., Ikeda, S., Yokoyama, T., Hataji, O., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.04.004 · Cited by 10

Mutation-Derived Long Noncoding RNA Signature Predicts Survival in Lung Adenocarcinoma

Yang, L., Guo, G., Yu, X., Wen, Y., Lin, Y., Zhang, R., Zhao, D., Huang, Z., Wang, G., Yan, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.780631 · Cited by 9

Association of Mutation Profiles with Postoperative Survival in Patients with Non–Small Cell Lung Cancer

Goto, T., Kunimasa, K., Hirotsu, Y., Nakagomi, T., Yokoyama, Y., Higuchi, R., Otake, S., Oyama, T., Amemiya, K., Mochizuki, H., et al. (2020) · Cancers · doi:10.3390/cancers12113472 · Cited by 9

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma

Zheng, Z.-R., Ku, H., Chen, K., Chiang, C., Wang, C.-L., Chen, C.-Y., Tsai, C., Huang, M.-S., Yu, C., Chen, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1063695 · Cited by 8

Untangling the KRAS mutated lung cancer subsets and its therapeutic implications

Kulshrestha, R., Kumar, P., Singh, A., Nupur, K., Spalgias, S., Mrigpuri, P., & Rajkumar (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00061-0 · Cited by 8

Non-Small-Cell Lung Cancer Patients Harboring TP53/KRAS Co-Mutation could Benefit from a PD-L1 Inhibitor

Zhang, C., Wang, K., Lin, J., & Wang, H. (2022) · Future Oncology · doi:10.2217/fon-2022-0295 · Cited by 8

Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non‐small cell lung cancer

Jiang, W., Cheng, H., Yu, L., Zhang, J., Wang, Y., Liang, Y., Lou, F., Wang, H., & Cao, S. (2022) · Cancer Medicine · doi:10.1002/cam4.5447 · Cited by 8

Targeted next generation sequencing identified a high frequency genetic mutated profile in wood smoke exposure-related lung adenocarcinoma patients

Soca‐Chafre, G., Hernández‐Pedro, N., Avilés‐Salas, A., Versón, C. A., Carrillo‐Sánchez, K., Cardona, A. F., Ávila‐Moreno, F., Barrios‐Bernal, P., Flores‐Estrada, D., & Arrieta, O. G. (2018) · Oncotarget · doi:10.18632/oncotarget.25369 · Cited by 8

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology

Alidousty, C., Baar, T., Heydt, C., Wagener‐Ryczek, S., Kron, A., Wolf, J., Buettner, R., & Schultheis, A. M. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.12.03 · Cited by 8

Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma

Qian, H., Hou, C., Zhang, Y., Ji, S., Zhong, C., Li, J., Zhang, Q., Huang, J., Li, C., & ChengJi (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.08.006 · Cited by 8

Genetic network and gene set enrichment analyses identify MND1 as potential diagnostic and therapeutic target gene for lung adenocarcinoma

Wei, J., Meng, G., Wu, J., Zhang, Q., & Zhang, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-88948-4 · Cited by 7

Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients

Xi, Y., Bai, Z., Gao, S., Guo, J., Zhang, Z., Zhang, H., Qu, L., Xu, B., Wang, W., Shan, G., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04794-z · Cited by 6

ROS1-rearranged non-small cell lung cancer: Understanding biology and optimizing management in the era of new approvals

Myall, N. J., & Das, M. S. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101133 · Cited by 6

EGFR TKI resistance in lung cancer cells using RNA sequencing and analytical bioinformatics tools

Howell, M., Green, R. J., Cianne, J., Dayhoff, G. W., Uversky, V. N., Mohapatra, S. S., & Mohapatra, S. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2153269 · Cited by 6

Implications of obstructive sleep apnea in lung adenocarcinoma: A valuable omission in cancer prognosis and immunotherapy

Qi, P., Qi, B., Ding, Y., Sun, J., Gu, C., Huo, S., Liu, Y., & Zhao, B. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.05.013 · Cited by 6

Precision medicine: success stories and challenges from science to implementation

Seyhan, A. A., & Carini, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13963-5.00008-x · Cited by 6

Determination of selpercatinib, a RET kinase inhibitor, in rat plasma and its application to a pharmacokinetic study

Wang, W., Shi, L., Jin, L., & Wang, K. (2020) · Biomedical Chromatography · doi:10.1002/bmc.5052 · Cited by 6

A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked

Wei, Z., Zhang, T., Hua, X., Hoang, P. H., Miraftab, M., Saha, M., McElderry, J. P., Sang, J., Lee, O. W., Hartman, C., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0581 · Cited by 5

Integrated multi-omic analysis and experiment reveals the role of endoplasmic reticulum stress in lung adenocarcinoma

Liu, Y., Lin, W. C., Qian, H., Yang, Y., Zhou, X., Wu, C., Pan, X., Liu, Y., & Wang, G. (2024) · BMC Medical Genomics · doi:10.1186/s12920-023-01785-4 · Cited by 5

Overexpression of 15-Hydroxyprostaglandin Dehydrogenase Inhibits A549 Lung Adenocarcinoma Cell Growth via Inducing Cell Cycle Arrest and Inhibiting Epithelial-Mesenchymal Transition

Wang, W., Yang, C., & Deng, H. (2021) · Cancer Management and Research · doi:10.2147/cmar.s331222 · Cited by 5

Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations

Kim, I. A., Hur, J. Y., Kim, H. J., Lee, S. A., Hwang, J. J., Kim, W. S., & Lee, K. Y. (2021) · Cancers · doi:10.3390/cancers13143632 · Cited by 5

Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer

Wang, Y., Liu, H., Yu, N., & Xiang, X. (2023) · Current Oncology · doi:10.3390/curroncol30090616 · Cited by 4

Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements

Kim, K., Kim, K. Y., Kang, H. S., Shin, A. Y., Kim, S. K., Park, C. K., Lee, S. H., Kim, S. J., Lim, J. U., & Yeo, C. D. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251316200 · Cited by 4

A Deep Learning Framework Integrating Tumor Microenvironmental Features Accurately Predicts Multiple Driver Gene Mutations in Lung Cancer Pathology Images

Pan, L., Luo, J., Nie, C., Fan, S., Wang, X., Peng, S., & Liang, Q. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0582 · Cited by 4

Panel Sequencing for Targeted Therapy Selection in Solid Tumors

Willard, N., Sholl, L. M., & Aisner, D. L. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.04.004 · Cited by 4

[Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].

(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.102.44 · Cited by 4

Prognostic and predictive effects of TP53 co-mutation in patients with non-small cell lung cancer with rare treatable driver mutations

Feng, J., Hueniken, K., Fan, Z. J., Zhan, L. J., Faour, E., Corke, L., Alghabban, A., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108452 · Cited by 4

Dual NGS Comparative Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Samples of Non-Small Cell Lung Carcinoma (NSCLC)

Buburuzan, L., Zamfir, M.-A. I., Ardeleanu, C. M., Muresan, A. H., Vasilescu, F., Hudiță, A., Costache, M., Gălățeanu, B., Pușcașu, A., Filippi, A., et al. (2022) · Cancers · doi:10.3390/cancers14246084 · Cited by 4

Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting ( ICCR )

Cooper, W. A., Webster, F., Butnor, K. J., Calabrese, F., Chou, T., Hwang, D. M., Kern, I., Popat, S., Sholl, L. M., Yatabe, Y., et al. (2024) · Histopathology · doi:10.1111/his.15313 · Cited by 3

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact

Carbone, M., Amos, C. I., Attanoos, R. L., Boeri, M., Bueno, R., Bunn, P. A., Chirieac, L. R., Cooper, B. T., Fennell, D. A., Galateau-Sallé, F., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.11.002 · Cited by 4

Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma

Ibusuki, R., Iwama, E., Shimauchi, A., Kawano, H., Tsuneoka, Y., Hashisako, M., Harada, T., Tsuchiya‐Kawano, Y., Nakatomi, K., Furuyama, K., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108018 · Cited by 3

Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations

Zhou, T., Zhou, H., Gao, F., 冯卫能, Jiang, W., Huang, L., Zhao, F., Chen, L., Ji, M., Zhu, J., et al. (2026) · JAMA · doi:10.1001/jama.2026.10599 · Cited by 3

Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis

Lin, K., Lin, J., Huang, Z., Fu, J., Yi, Q., Cai, J., Khan, M. B., Yuan, Y., & Bu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881493 · Cited by 3

Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF ‐mutation status?

Ma, S., Wang, R., Peng, Q., Liu, Y., Qian, J., Li, M., Li, K., Huang, Z., Wu, L., & Xie, D. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15248 · Cited by 3

A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer

Chan, S. W. S., Zeng, J., Young, J., Barghout, S. H., Al-Agha, F., Raptis, S., Brown, M. C., Liu, G., Juergens, R. A., & Jao, K. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.10.009 · Cited by 3

Association of PI3K/AKT/mTOR Pathway with Cancer and Its Therapeutic Implications

Saleem, S., Bashir, I., Khan, M. S., & Ahanger, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_3 · Cited by 3

A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations

Blakely, C. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2861 · Cited by 3

Correlation analysis between serum neuron-specific enolase and the detection of gene mutations in lung adenocarcinoma

Xu, F.-Z., & Zhang, Y. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1633 · Cited by 3

Immune subgroup analysis for non-small cell lung cancer may be a good choice for evaluating therapeutic efficacy and prognosis

Tian, Y., Wang, J., Wen, Q., Su, G., & Sun, Y. (2021) · Aging · doi:10.18632/aging.202941 · Cited by 3

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC

Tompkins, W. P., Grady, C. B., Hwang, W., Chandrasekhara, K., McCoach, C. E., Sun, F., Liu, G., Patel, D., Nieva, J. J., Herrmann, A. C., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100669 · Cited by 3

Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases

Krstić, V. Ć., Soldatović, I., Samardžić, N., Gajić, M., Kontić, M., Reljić, A., Savić, M., Milenković, M. R., & Jovanović, D. M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120801 · Cited by 3

Significance of testing for TP53 gene mutations in lung adenocarcinoma using targeted gene sequencing

Matsumura, Y., Owada, Y., & Suzuki, H. Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.66 · Cited by 3

Approach to stage IV non-small-cell lung cancer: how to select among first-line therapy options?

Pacheco, J. M. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000659 · Cited by 3

Identification of Tumor Microenvironment-Related Prognostic lncRNAs in Lung Adenocarcinoma

Yuan, L., Feng, L., Wang, S., Yi, H., Li, F., & Mao, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719812 · Cited by 3

Transcriptomic heterogeneity of driver gene mutations reveals novel mutual exclusivity and improves exploration of functional associations

Lan, Y., Liu, W., Zhang, W., Hu, J. R., Zhu, X., Wan, L., Suru, A., Ping, Y., & Xiao, Y. (2021) · Cancer Medicine · doi:10.1002/cam4.4039 · Cited by 2

Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism

Xie, B., Qiu, Y., Zhou, J., Du, D., Ma, H., Ji, J., Zhu, L., & Zhang, W. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02884-x · Cited by 2

Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies

Sholl, L. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.002 · Cited by 2

Genomic Characterization of NSCLC in African Americans: A Step Toward “Race-Aware” Precision Medicine

Mamdani, H. M., & Schwartz, A. G. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.009 · Cited by 2

COL1A1, COL1A2, COL3A1 and DCN are Potential Biomarkers to Predict Progression from Smokers to Suffering from Lung AdenocarcinomaPreprint

Chen, J., Chen, S., Wang, F., Wang, S., & Wu, W. (2020) · doi:10.21203/rs.3.rs-76976/v1 · Cited by 2

Relationship between early lung adenocarcinoma and multiple driving genes based on artificial intelligence medical images of pulmonary nodules

Yin, Y., Lu, J., Tong, J., Cheng, Y., & Zhang, K. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1142795 · Cited by 1

Efficient Method to Classify Lung Cancer from CT Images Based on ARIMA-CF-LSTM Approach

Suganthi, D., Divyashree, D. P., Upadhye, S., Tamijeselvan, S., Mounika, P., & Aparna, N. (2025) · International Conference on Data Science and Network Security (ICDSNS) · doi:10.1109/icdsns65743.2025.11168620 · Cited by 1

Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis

Li, Y., Wen, Y., Zhang, W., Zhao, Y., Zhou, L., Zeng, X., Kang, X., & Li, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1620485 · Cited by 1

The effect of smoking and TP53 mutations on molecular-targeted therapy in lung adenocarcinoma patients

Okuda, K., Haneda, H., Yokota, K., Tatematsu, T., & Nakanishi, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.43 · Cited by 1

Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic

Pešek, M., Skřičková, J., Kolek, V., Šatánková, M., Koubková, L., Roubec, J., Chloupková, R., Černovská, M., Benejová, A., Kultan, J., et al. (2018) · Klinicka onkologie · doi:10.14735/amko2018207 · Cited by 1

BRAF: Novel Therapies for an Emerging Target

Myall, N. J., & Padda, S. K. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_4 · Cited by 1

Cancer bronchique et tabac : mise à jour

Sakhri, L., & Bertocchi, M. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2018.06.013 · Cited by 1

Molekulare therapeutische Stratifizierung des nichtkleinzelligen Lungenkarzinoms

Lang, S. M., & Rachow, T. (2020) · Wiener klinisches Magazin · doi:10.1007/s00740-020-00371-z · Cited by 1

Expression and Gene Regulation Network of NUDT21 in Lung Adenocarcinoma and Prediction of Anticancer Components of Pinellia Ternata Based on Data MiningPreprint

Situ, Y., Li-na, L. O. N. G., Li, H., Fang, Z., & Hong, N. (2021) · Research Square · doi:10.21203/rs.3.rs-411545/v1 · Cited by 1

A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocolPreprint

Sadeghi, S., Kiaei, A. A., Boush, M., Salari, N., Mohammadi, M., Safaei, D., Mahboubi, M., Tajfam, A., & Moghadam, S. (2024) · medRxiv · doi:10.1101/2024.04.14.24304384 · Cited by 1

Expanding the gamut of circulating tumor DNA applications

Kaumaya, M., & Halmos, B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.87

Prioritizing mutational profiling for targeted therapy of lung adenocarcinoma

Sinjab, A. F., & Tfayli, A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.02.29

Molekulare therapeutische Stratifizierung des nichtkleinzelligen Lungenkarzinoms

Lang, S. M., & Rachow, T. (2020) · Der Onkologe · doi:10.1007/s00761-020-00787-6

Establishment, Characterisation And Mirna Transcriptome Profiling Of Spheroid-Enriched Cells With Breast Cancer Stem Cell Properties

Boo, L. (2020)

Identification of Mechanisms of Resistance to ALK Inhibitors. Next-generation sequencing-based liquid biopsy profiling: A step towards personalized treatment.Preprint

Sánchez‐Herrero, E., Serna‐Blasco, R., Ivanchuk, V., García‐Campelo, R., Dómine, M., Sánchez, J. M., Massutí, B., Reguart, N., Camps, C., Sanz‐Moreno, S., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-86055/v1

Association of expression and genotypes of thymidylate synthase in non-small cell lung cancer patients with different clinicopathological characteristics

Chen, J., Chen, H.-J., & Chen, P. (2021) · Pteridines · doi:10.1515/pteridines-2020-0013

Network Pharmacology Revealed the mechanism of Platycodon grandiflorum in Lung Cancer TreatmentPreprint

Chen, X., Zhang, R., Wang, R., & Yao, C. (2020) · Research Square · doi:10.21203/rs.3.rs-58086/v1

Akciğer Kanserinde Güncel Genetik Algoritma ve Tedavi Seçenekleri

Arslan, S. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub80.c247

Akciğer Kanserine Moleküler Terapötik Yaklaşım

Bayrak, B. Y. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub80.c356

Hematolojik Malignitelerde Sitogenetiğin Tanısal ve Terapötik Yönleri

Şahin, H. (2023) · Özgür Yayınları eBooks · doi:10.58830/ozgur.pub80.c359

Que faut-il connaître de la classification anatomopathologique des cancers pulmonaires ?

Lantuéjoul, S. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00127-1

Adoption of Artificial Intelligence in Human and Clinical Genomics, volume II

(2024) · Frontiers research topics · doi:10.3389/978-2-8325-5055-7

Impact of TP53 mutations on brain metastasis control in non-small cell lung cancer patients undergoing stereotactic radiosurgery.

Leng, J. X., Su, C., Carpenter, D. J., Floyd, W., Vaios, E., Shenker, R. F., Hendrickson, P. G., Giles, W., Mullikin, T. C., Floyd, S., et al. (2024) · PubMed Central

Exploring the Significance of p53 Gene in Lung Cancer: Etiological Factors, Clinical Implications, and Therapeutic Approaches

Sadeghvand, S., Nasiri, H., Sadighi, A., Heris, J. A., Shahabi, P., Shomali, N., Nasab, R. M., Hejazi, S., Bahadori, A., & Akbari, M. (2023) · Multidisciplinary Cancer Investigation · doi:10.61186/mci.7.4.1

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors

Myall, N. J., Whisenant, J. G., Neal, J. W., Iams, W. T., Reckamp, K. L., York, S. J., Berry, L. D., Shyr, Y., Horn, L., Wakelee, H. A., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100757

Deciphering bidirectional causal links between oxidative stress and lung cancer risk through Mendelian randomization

Chen, X., Zeng, J., Cao, F., Cai, J., Ma, X., & Pu, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-03289-2

Additional file 9 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144525

Additional file 2 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Bertucci, F., Gonçalvès, A., Guillé, A., Adélaı̈de, J., Garnier, S., Carbuccia, N., Billon, E., Finetti, P., Sfumato, P., Monneur, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14615296

Additional file 4 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144495

Additional file 7 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144510

Additional file 1 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144483

Additional file 6 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144501

Additional file 2 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144486

Additional file 11 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144480

Additional file 1 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Bertucci, F., Gonçalvès, A., Guillé, A., Adélaı̈de, J., Garnier, S., Carbuccia, N., Billon, E., Finetti, P., Sfumato, P., Monneur, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14615293

Additional file 3 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144489

Additional file 5 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144498

Additional file 4 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Bertucci, F., Gonçalvès, A., Guillé, A., Adélaı̈de, J., Garnier, S., Carbuccia, N., Billon, E., Finetti, P., Sfumato, P., Monneur, A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14615305

Additional file 10 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144474

Additional file 8 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144516

A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).

Johnson, B. E., Kris, M. G., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Wistuba, I. I., Franklin, W. A., Ladanyi, M., Su, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8019 · Cited by 60

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).

Kris, M. G., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Aronson, S. L., Engelman, J. A., Shyr, Y., Khuri, F. R., Rudin, C. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.18_suppl.cra7506 · Cited by 141

P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor

Kris, M. G., Aisner, D. L., Sholl, L., Berry, L. D., Rossi, M., Chen, H., Fujimoto, J., Moreira, A., Ramalingam, S. S., Villaruz, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1633

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

Hsu, K.-H., Ho, C., Hsia, T., Tseng, J., Su, K., Wu, M., Chiu, K.-L., Yang, T., Chen, K.-C., Ooi, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120852 · Cited by 127

The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies

Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 109